Related Experiment Video
Updated: Aug 5, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
Trazodone-induced parkinsonism: A case report
Background:
Trazodone is prescribed off-label to treat insomnia, especially in older, not depressed adults. At low doses, it blocks histamine-1 (H1) receptors having a hypnotic effect. Unusual but potentially severe side effects of trazodone include suicidal behavior, excess sedation, QT prolongation, and priapism. Three case studies have been published in the last four decades describing trazodone-induced parkinsonism.
Case Presentation:
A 78-year-old Caucasian male with a past medical history of paroxysmal atrial fibrillation (on amiodarone), major depressive disorder, chronic obstructive pulmonary disease, hypothyroidism, and obstructive sleep apnea, was prescribed trazodone for his chronic insomnia. After 1 month, he was seen in the emergency department (ED) with complaints of coarse tremors of his upper extremities and could not write with a pen anymore due to shaking. He noticed dragging of his feet while walking for over a month, which caused him to have multiple falls and significantly impacted his activities of daily living. On clinical exam, the patient had bilateral cogwheel rigidity in ankles and shuffling gait. Trazodone was discontinued, and his symptoms resolved within a week.
Conclusion:
Trazodone was likely causing parkinsonism in our patient. Amiodarone may have hindered trazodone metabolism causing higher levels in blood. Multiple mechanisms of trazodone's effect on dopamine have been suggested, but the serotonin-dopamine system interaction remains significant. Physicians need to contemplate the benefits and detriments before adding more medications to the list for older adults. Polypharmacy can amplify the adverse effects of a drug that might not be seen in everyday practice.
Related Concept Videos
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Alterations in Muscle Tone lll

